Acotiamide, a new selective inhibitor of acetylcholinesterase (AChE) that impedes the degradation of ACh expelled from the parasympathetic nerve endings and elevates ACh levels in the synaptic gap, has been administered to manage functional dyspepsia. The gene discussed is ACHE; the disease is dyspepsia.